VeonGen Therapeutics
PrivateLast Round
Series A
Nov 28, 2019
Company Overview
VeonGen Therapeutics operates in Healthcare & Life Sciences and is based in Planegg. Its latest recorded funding round was a Series A round in November 2019.
VeonGen Therapeutics is a biotechnology company that develops innovative gene therapies for ophthalmic diseases and other genetic conditions using proprietary adeno-associated virus (AAV) technology platforms.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VeonGen Therapeutics Comparables
Compare VeonGen Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ray Therapeutics | 78% | |
| Ascidian Therapeutics | 75% | |
| Cure Genetics | 74% |
For institutional investors. Book with your work email.
VeonGen Therapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
VeonGen Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ludwig-Maximilians-Universität München | Series A |
| HongShan Capital Group (HSG) | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 15, 2026
Monthly visitors increased 224% MoM.
- Apr 5, 2026
Monthly visitors increased 73% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 8, 2026
VeonGen Therapeutics GmbH develops VG801, a dual adeno-associated viral vector gene therapy that delivers the ABCA4 gene in two halves through a one-time eye injection; the therapy remains in early-stage testing for a condition with no approved treatments.
For institutional investors. Book with your work email.
VeonGen Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about VeonGen Therapeutics's valuation, stock price, and market status.
Is VeonGen Therapeutics a public or private company?
VeonGen Therapeutics is a private company.
What is the current stock price of VeonGen Therapeutics?
VeonGen Therapeutics is a private company, so its shares have no public market price. Caplight tracks VeonGen Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is VeonGen Therapeutics worth (valuation)?
Valuation information for VeonGen Therapeutics is not publicly available.
Can I buy VeonGen Therapeutics stock?
VeonGen Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was VeonGen Therapeutics's last funding round?
VeonGen Therapeutics's most recent funding round was Series A on November 28, 2019.
Who are the main investors in VeonGen Therapeutics?
Key investors in VeonGen Therapeutics include HongShan Capital Group (HSG).
Will VeonGen Therapeutics IPO soon?
No public IPO plans have been announced for VeonGen Therapeutics.
How can I track VeonGen Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in VeonGen Therapeutics's shares on secondary markets.